Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Nasus Pharma Ltd. (NSRX) had Return on Tangible Equity of -209.72% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-5.86M |
|
-- |
|
-- |
|
$4.90M |
|
$-4.90M |
|
$-0.90M |
|
$-5.80M |
|
$-5.80M |
|
$-5.80M |
|
$-5.80M |
|
$-5.86M |
|
$-5.80M |
|
$-4.90M |
|
$-4.90M |
|
8.01M |
|
8.01M |
|
$-0.72 |
|
$-0.72 |
|
| Balance Sheet Financials | |
$4.86M |
|
$0.01M |
|
$0.15M |
|
$5.00M |
|
$2.16M |
|
-- |
|
$0.07M |
|
$2.24M |
|
$2.77M |
|
$2.77M |
|
$2.77M |
|
9.02M |
|
| Cash Flow Statement Financials | |
$-4.92M |
|
$-3.01M |
|
$8.92M |
|
$0.31M |
|
$1.29M |
|
$0.98M |
|
$0.45M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.24 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.93M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-209.72% |
|
|
Return on Tangible Equity |
-209.72% |
-116.01% |
|
-209.72% |
|
$0.31 |
|
$-0.62 |
|
$-0.61 |
|